Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 29 2017 - 6:00PM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a commercial-stage
biopharmaceutical company focused on the discovery and development
of precision genetic medicines to treat rare neuromuscular
diseases, granted equity awards on December 29, 2017, that were
previously approved by the Compensation Committee of its Board of
Directors under Sarepta’s 2014 Employment Commencement Incentive
Plan, as a material inducement to employment to ten individuals
hired by Sarepta in December 2017. The equity awards were approved
in accordance with Nasdaq Listing Rule 5635(c)(4).
The employees received, in the aggregate, options to purchase
29,625 shares of Sarepta's common stock. The options have an
exercise price of $55.64 per share, which is equal to the closing
price of Sarepta's common stock on December 29, 2017. One-fourth of
the shares underlying each employee’s option will vest on the one
year anniversary of his or her date of hire and thereafter 1/48th
of the shares underlying each employee’s option will vest monthly,
such that the shares underlying the option granted to each employee
will be fully vested on the fourth anniversary of his or her date
of hire, in each case, subject to each such employee’s continued
employment with Sarepta on such vesting dates.
About Sarepta TherapeuticsSarepta
Therapeutics is a commercial-stage biopharmaceutical company
focused on the discovery and development of precision genetic
medicines to treat rare neuromuscular diseases. The Company is
primarily focused on rapidly advancing the development of its
potentially disease-modifying Duchenne muscular dystrophy (DMD)
drug candidates. For more information, please visit
www.sarepta.com.
Internet Posting of InformationWe routinely
post information that may be important to investors in the 'For
Investors' section of our website at www.sarepta.com. We
encourage investors and potential investors to consult our website
regularly for important information about us.
Source: Sarepta Therapeutics, Inc.
Media and Investors: Sarepta Therapeutics, Inc. Ian Estepan,
617-274-4052 iestepan@sarepta.com or W2O Group Brian Reid,
212-257-6725 breid@w2ogroup.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024